Elevated Levels of PDGF-BB and VEGF Are Associated With a Decreased Risk of Readmission or Death in Children With

Mary G Slaughter1, Samina Bhumbra1, Kagan A Mellencamp1

  • 1Ryan White Center for Pediatric Infectious Disease and Global Health, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA.

PubMed

Insights

Children with severe malarial anemia have a high risk of readmission or death. Elevated levels of platelet-derived growth factor-BB (PDGF-BB) and vascular endothelial growth factor (VEGF) are linked to a lower risk of readmission or death.

Area of Science:

  • Pediatrics
  • Tropical Medicine
  • Hematology

Background:

  • Children with severe malarial anemia (SMA) face significant risks of readmission and mortality post-discharge.
  • Dysregulation in hematopoiesis, vascular growth factors, and endothelial function may contribute to these adverse outcomes.

Purpose of the Study:

  • To investigate the association between specific biomarkers in children with SMA and their risk of readmission or death within 12 months.
  • To determine if markers of hematopoiesis, vascular growth, and endothelial function predict post-discharge outcomes in pediatric SMA patients.

Main Methods:

  • Plasma samples were collected from 145 children (18 months to 12 years) with SMA upon admission in Kampala, Uganda.
  • Levels of 10 biomarkers were measured and correlated with 12-month follow-up outcomes, including readmission and mortality.

Main Results:

  • Elevated admission plasma levels of platelet-derived growth factor-BB (PDGF-BB) and vascular endothelial growth factor (VEGF) were independently associated with a reduced risk of readmission or death.
  • These growth factors significantly decreased the risk of readmission due to severe malaria, but not uncomplicated malaria.

Conclusions:

  • Higher plasma PDGF-BB and VEGF levels in children with SMA are protective against readmission and death within a year post-discharge.
  • Angiogenic factors PDGF-BB and VEGF appear to mitigate the risk of recurrent severe malaria, improving overall outcomes.
Abstract